Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
3rd Gen CD19 CAR T for Refractory B-Cell Malignancies
NCT03068416Phase 2Completed
- Sponsor
- Uppsala University
- Start
- Sep 2017
- Primary completion
- Aug 2021
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
A Phase 2 trial of CD19.CAR-CD28-CD137zeta in B cell lymphoma, B-cell leukemia (BCL), sponsored by Uppsala University. Started Sep 2017; status: completed.
02
Drugs
CD19.CAR-CD28-CD137zeta
03
Conditions
B cell lymphomaB-cell leukemia (BCL)
Beyond the preview
Go deeper on NCT03068416.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03068416.